Cargando…
Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
BACKGROUND: To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate. METHODS: In this double-blind, placebo-controlled phase 3 trial, biologic-naïv...
Autores principales: | Zeng, Xiaofeng, Liu, Ju, Liu, Xiumei, Wu, Lijun, Liu, Yi, Liao, Xiangping, Liu, Huaxiang, Hu, Jiankang, Lu, Xin, Chen, Linjie, Xu, Jian, Jiang, Zhenyu, Lu, Fu-ai, Wu, Huaxiang, Li, Ying, Wang, Qingyu, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185960/ https://www.ncbi.nlm.nih.gov/pubmed/35689239 http://dx.doi.org/10.1186/s13075-022-02821-x |
Ejemplares similares
-
Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019) -
Persistence of strong and switchable ferroelectricity despite vacancies
por: Raeliarijaona, Aldo, et al.
Publicado: (2017) -
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020) -
MicroRNA-4423-3p inhibits proliferation of fibroblast-like synoviocytes by targeting matrix metalloproteinase 13 in rheumatoid arthritis
por: Xu, Weihong, et al.
Publicado: (2021) -
Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)